CLAIMS:

1. An anti-TNF antibody or binding fragment thereof comprising a heavy chain or heavy chain fragment having a variable region, wherein said variable region of the heavy chain has the sequence given in SEQ ID NO: 12 or 16, and wherein the antibody or binding fragment further comprises a light chain or fragment thereof having a variable region, wherein said variable region of the light chain has the sequence given in SEQ ID NO: 11 or 15.
2. An anti-TNF antibody or binding fragment thereof according to claim 1, having a heavy chain comprising the sequence given in SEQ ID NO: 12 and a light chain comprising the sequence given in SEQ ID NO: 11.
3. An anti-TNF antibody or binding fragment thereof according to claim 1, having a heavy chain comprising the sequence given in SEQ ID NO: 16 and a light chain comprising the sequence given in SEQ ID NO: 15.
4. An anti-TNF antibody or binding fragment thereof according to claim 1, wherein the antibody is humanized.
5. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 4, wherein the antibody or binding fragment is a scFv, dsscFv, Fv, Fab, Fab', Fab-Fv, or Fab-dsFv fragment.
6. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 5, wherein the antibody or binding fragment is conjugated to a polymer for example selected from starch, albumin and polyethylene glycol (PEG).
7. An anti-TNF antibody or binding fragment thereof according to claim 6, wherein the polymer is PEG, for example with a molecular weight in the range 5 to 50kDa.
8. An anti-TNF antibody according to any one of claims 1 to 4, wherein the antibody is a full length antibody.
9. An anti-TNF antibody according to claim 8, wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.
10. An anti-TNF antibody or binding fragment thereof which binds to the same epitope of human TNF as the antibody of claim 1 to 3.
11. An anti-TNF antibody or binding fragment thereof which cross-blocks the binding of an antibody of claim 1 to 3 to human TNF or is cross-blocked from binding human TNF by an antibody of claim 1 to 3.
12. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 11, which is humanized.
13. An anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 12, which has a binding affinity for human TNF of 150pM or higher affinity.

14. A multispecific antibody comprising an anti-TNF antibody or binding fragment thereof according to any one of claims 1 to 5 or any one of claims 10 to 13.
15. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to 14.
16. A cloning or expression vector comprising one or more DNA sequences according to claim 15.
17. A vector according to claim 16, wherein the vector comprises (i) the sequence given in SEQ ID NO: 17, 18 and/or 22.
18. A host cell comprising one or more cloning or expression vectors according to claim 16 or claim 17.
19. A process for the production of an antibody having binding specificity for human TNF, comprising culturing the host cell of claim 18 and isolating the antibody.
20. A pharmaceutical composition comprising an anti-TNF antibody or binding fragment thereof as defined in any one of claims 1 to 14 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
21. A pharmaceutical composition according to claim 20 comprising other active ingredients.
22. An antibody or binding fragment thereof as defined in any one of claims 1 to 14 or a composition as defined in claim 20 or 21 for use in therapy.
23. An antibody or binding fragment thereof as defined in any one of claims 1 to 14 or a composition as defined in claim 20 or 21 for use in the treatment of one or more of rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson’s disease and epilepsy.
24. Use of an antibody or binding fragment thereof as defined in any one of claims 1 to 14 or a composition as defined in claim 20 or claim 21 in the manufacture of a medicament for the treatment of one or more of rheumatoid arthritis, Crohn's disease, psoriasis, systemic lupus erythematosus, Alzheimer's disease, Parkinson’s disease and epilepsy, wherein a patient is to be administered with a therapeutically effective amount of said antibody or binding fragment thereof or said composition.